

INFORMATION DISCLOSURE STATEMENT


Applicant : Botstein, et al.
App. No : 10/033,167
Filed : December 27, 2001
For : SECRETED AND
TRANSMEMBRANE POLYPEPTIDES
AND NUCLEIC ACIDS ENCODING
THE SAME
Examiner : Fredman, J.
Art Unit : 1637

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 15, 2005

(Date)


AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 51 references to be considered by the Examiner. Also enclosed are 38 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 15, 2005


By: 
AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

06/20/2005 CCHAU1 00000008 10033167

01 FC:1806

180.00 OP

1770636:061505



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 3

Application No.	10/033,167
Filing Date	December 27, 2001
First Named Inventor	Botstein, et al.
Art Unit	1637
Examiner	Fredman, J.
Attorney Docket No.	GNE.2930R1C10

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, Dean	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582	05-08-2001	Rodier, et al.	
	6	6,395,306	05-28-2002	Cui, et al.	
	7	6,414,117	07-02-2002	Levinson, D. A.	
	8	6,465,185	10-15-2002	Goldfine, et al.	
	9	6,498,235	12-24-2002	Sheppard, et al.	
	10	6,562,343	05-13-2003	Levinson, D. A.	
	11	6,645,499	11-11-2003	Lal, et al.	
	12	6,730,502	05-04-2004	Van Hijum, et al.	
	13	6,737,522	05-18-2004	Sundick, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	14	WO 97/38085	10-16-1997	California Pacific Medical Center		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	ALLMAN, et al. 1996. <i>Blood</i> , Vol 87, No. 12, pp. 5257-5288.	
	16	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	17	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	18	ALITALO 1984. Amplification of cellular oncogenes in cancer cells. <i>Med. Biol.</i> , 62:304-317	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Application No.	10/033,167
	Filing Date	December 27, 2001
	First Named Inventor	Botstein, et al.
	Art Unit	1637
(Multiple sheets used when necessary)	Examiner	Fredman, J.
SHEET 2 OF 3	Attorney Docket No.	GNE.2930R1C10

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	19	BANHASSY, et al. 2004. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. <i>BMC Gastroenterology</i> , 4:22-34.	
	20	BIECHE, et al. 1998. Novel Approach to Quantitative Polymerase Chain Reaction Using Real-Time Detection: Application to the Detection of Gene Amplification in Breast Cancer. <i>Int. J. Cancer</i> . 78:661-666.	
	21	BLANCATO, et al. 2004. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, <i>in situ</i> hybridization and immunohistochemical analyses. <i>British Journal of Cancer</i> , 90(8), 1612-1619.	
	22	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. <i>Molecular & Cellular Proteomics</i> 1.4, 304-313.	
	23	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , Vol. 15, No. 16, pp. 4392-4401.	
	24	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C β II Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research</i> , Vol. 61, pp.1375-1381.	
	25	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	26	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. <i>Molecular and Cellular Biology</i> , 1720-1730.	
	27	HANCOCK, W. S. 2004. Do we have enough biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	28	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	29	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , Vol. 19, pp. 1862- 1871.	
	30	HEID, et al. 1996. Real Time Quantitative PCR. <i>Genome Res</i> . 6:986-994.	
	31	HIGUCHI, et al. April 1992. Simultaneous Amplification and Detection of Specific DNA Sequences. <i>Biotechnology</i> , 10:413-417.	
	32	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. <i>Journal of Proteome Research</i> , Vol. 2, pp. 405-412.	
	33	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. <i>Cancer Research</i> , 62:6240-6245.	
	34	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	
	35	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, <i>National Academy of Sciences of the United States of America</i> , Vol. 83, No. 11, pp. 4049-4052	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Application No.	10/033,167
	Filing Date	December 27, 2001
	First Named Inventor	Botstein, et al.
	Art Unit	1637
(Multiple sheets used when necessary)	Examiner	Fredman, J.
SHEET 3 OF 3	Attorney Docket No.	GNE.2930R1C10

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	36	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	37	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	38	LIVAK, et al. 1995. Oligonucleotides with Fluorescent Dyes at Opposite Ends Provide a Quenched Probe System Useful for Detecting PCR Product and Nucleic Acid Hybridization. <i>PCR Methods Appl</i> 4:357-362.	
	39	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	40	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	41	MERLINO, et al. 1985. Elevated Epidermal Growth Factor Receptor Gene Copy Number and Expression in a Squamous Carcinoma Cell Line. <i>J. Clin. Invest.</i> , 75:1077-1079	
	42	OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro recombination reaction. <i>Nucleic Acids Research</i> , Vol. 29, No e22, pp.1-8.	
	43	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	44	PENNICA, et al. 1998. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1 transformed cells and aberrantly expressed in human colon tumors. <i>Proc. Natl. Acad. Sci. USA</i> . 95(25):14717-14722.	
	45	PITTI, et al., 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. <i>Nature</i> . 396(6712):699-703.	
	46	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	47	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , Vol.5: pp. 411-421.	
	48	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu</i> , 1(27):165-190.	
	49	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	
	50	WANG, et al. 1996. mRNA differential display: Application in the discovery of novel pharmacological targets. <i>TIPS</i> , 17:276-279.	
	51	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	

1769791
061505

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.